Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid
about
Comparative Study of Photodynamic Therapy with Topical Methyl Aminolevulinate versus 5-Aminolevulinic Acid for Facial Actinic Keratosis with Long-Term Follow-Up.Dual-channel red/blue fluorescence dosimetry with broadband reflectance spectroscopic correction measures protoporphyrin IX production during photodynamic therapy of actinic keratosisEnhanced sonophoretic delivery of 5-aminolevulinic acid: preliminary human ex vivo permeation data.Migraine and beyond: cardiovascular therapeutic potential for CGRP modulators.Aminolevulinic acid: pharmacological profile and clinical indication.Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer.Optimization and therapeutic effects of PDT mediated by ALA and MAL in the treatment of cutaneous malignant lesions: A comparative study.Noninvasive Optical Imaging of UV-Induced Squamous Cell Carcinoma in Murine Skin: Studies of Early Tumor Development and Vitamin D Enhancement of Protoporphyrin IX ProductionA Formulation Study of 5-Aminolevulinic Encapsulated in DPPC Liposomes in Melanoma Treatment.Heterogeneity of fluorescence in psoriasis after application of 5-aminolaevulinic acid: an immunohistochemical study.The effects of keratolytic pretreatment prior to fluorescence diagnosis and photodynamic therapy with aminolevulinic acid-induced porphyrins in psoriasis.In vitro/in vivo correlations between transdermal delivery of 5-aminolaevulinic acid and cutaneous protoporphyrin IX accumulation and effect of formulation.Topical aminolaevulinic acid-based photodynamic therapy as a treatment option for psoriasis? Results of a randomized, observer-blinded study.[Daylight photodynamic therapy : Back to the future?]
P2860
Q33801978-15DB3094-E316-4206-840F-F0A9FA4FABEFQ33848250-4F6933B8-3BF8-4010-A997-1C626EDAB7F3Q34294126-BD048952-4519-48BC-8A8D-32F3A7FD30E2Q34481505-C3CAA658-7397-4B01-8043-78AA1E5F3AE1Q34481510-60AF8631-11E6-479F-9794-65BC7B92F952Q34570370-13074A28-C47E-4754-B1F6-1E2F6E0C8772Q36139442-0C5061D2-AF4E-4DDE-83C2-890E016FABAAQ36244912-53F37AA0-1626-4C04-B1BA-5E87590FB2B1Q37096898-78502267-53C8-41C8-89FF-1FF181D06761Q39765646-A3FBEEB2-B77B-4D51-8FE0-4D8834101B18Q43260829-809D36D8-61DF-4329-8799-ECC40B1C989EQ43986459-4701BF74-BA83-49A0-A927-9526605A02D9Q45280035-B5BA01C2-A7C4-4869-BB8D-BF057CA3BA1FQ50077758-5B8CDFAB-F3B8-42C5-9FBB-17F09BA96321
P2860
Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid
@ast
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid
@en
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid.
@nl
type
label
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid
@ast
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid
@en
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid.
@nl
prefLabel
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid
@ast
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid
@en
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid.
@nl
P2093
P2860
P921
P356
P1476
Optimum porphyrin accumulation ...... of delta-aminolaevulinic acid
@en
P2093
Schulte KW
P2860
P2888
P304
P356
10.1038/SJ.BJC.6690255
P407
P577
1999-03-01T00:00:00Z
P5875
P6179
1013760847